Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia

References

1. ↵
   1. Anderson TJ,
   2. Gregoire J,
   3. Hegele RA,
   4. Couture P,
   5. Mancini GB,
   6. McPherson R,
   7. et al.

   (2013) 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 29:151–167.

   OpenUrlCrossRefPubMed
2. ↵
   1. Naito R,
   2. Kasai T

   (2015) Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives. World J Cardiol 7:119–124.

   OpenUrlCrossRefPubMed
3. ↵
   1. Catapano AL,
   2. Ference BA

   (2015) IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease. Atherosclerosis 241:498–501.

   OpenUrlCrossRefPubMed
4. ↵
   1. Al-Shehri AM

   (2014) Prevalence and pattern of lipid disorders in Saudi patients with angiographically documented coronary artery disease. J Family Community Med 21:166–169.

   OpenUrl
5. ↵
   1. European Association for Cardiovascular Prevention & Rehabilitation,
   2. Reiner Z,
   3. Catapano AL,
   4. De Backer G,
   5. Graham I,
   6. Taskinen MR,
   7. et al.

   (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769–1818.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Al Sifri SN,
   2. Almahmeed W,
   3. Azar S,
   4. Okkeh O,
   5. Bramlage P,
   6. Junger C,
   7. et al.

   (2014) Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. PLoS One 9:e84350.

   OpenUrl
7. ↵
   1. Arafah M,
   2. Al-Hinai AT,
   3. Al Mahmeed W,
   4. Al-Rasadi K,
   5. Al Tamimi O,
   6. Al Herz S,
   7. et al.

   (2014) Centralized pan-Middle East Survey on the undertreatment of hypercholesterolemia: results from the CEPHEUS study in Arabian Gulf countries. Angiology 65:919–926.

   OpenUrlCrossRefPubMed
8. ↵
   1. Kotseva K,
   2. Wood D,
   3. De Bacquer D,
   4. De Backer G,
   5. Ryden L,
   6. Jennings C,
   7. et al.

   (2016) EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 23:636–648.

   OpenUrlCrossRefPubMed
9. ↵
   1. Al Shammeri O,
   2. Stafford RS,
   3. Alzenaidi A,
   4. Al-Hutaly B,
   5. Abdulmonem A

   (2014) Quality of medical management in coronary artery disease. Ann Saudi Med 34:488–493.

   OpenUrl
10. ↵
    1. Gitt AK,
    2. Lautsch D,
    3. Ferrieres J,
    4. De Ferrari GM,
    5. Vyas A,
    6. Baxter CA,
    7. et al.

    (2017) Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis 266:158–166.

    OpenUrl
11. 1. Roberts WC

    (1997) The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 80:106–107.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Al-Nozha MM,
    2. Arafah MR,
    3. Al-Maatouq MA,
    4. Khalil MZ,
    5. Khan NB,
    6. Al-Marzouki K,
    7. et al.

    (2008) Hyperlipidemia in Saudi Arabia. Saudi Med J 29:282–287.

    OpenUrlPubMed
13. ↵
    1. Gitt AK,
    2. Lautsch D,
    3. Ferrieres J,
    4. Kastelein J,
    5. Drexel H,
    6. Horack M,
    7. et al.

    (2016) Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis 255:200–209.

    OpenUrl
14. ↵
    1. Yatsuya H,
    2. Li Y,
    3. Hilawe EH,
    4. Ota A,
    5. Wang C,
    6. Chiang C,
    7. et al.

    (2014) Global trend in overweight and obesity and its association with cardiovascular disease incidence. Circ J 78:2807–2818.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Midhet FM,
    2. Sharaf FK

    (2011) Impact of health education on lifestyles in central Saudi Arabia. Saudi Med J 32:71–76.

    OpenUrlPubMed
16. ↵
    1. Nicholls SJ,
    2. Ballantyne CM,
    3. Barter PJ,
    4. Chapman MJ,
    5. Erbel RM,
    6. Libby P,
    7. et al.

    (2011) Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365:2078–2087.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    1. Cannon CP,
    2. Braunwald E,
    3. McCabe CH,
    4. Rader DJ,
    5. Rouleau JL,
    6. Belder R,
    7. et al.

    (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Arnold SV,
    2. Kosiborod M,
    3. Tang F,
    4. Zhao Z,
    5. Maddox TM,
    6. McCollam PL,
    7. et al.

    (2014) Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation 129:1303–1309.

    OpenUrlAbstract/FREE Full Text
19. ↵
    1. Cannon CP,
    2. Steinberg BA,
    3. Murphy SA,
    4. Mega JL,
    5. Braunwald E

    (2006) Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48:438–445.

    OpenUrlFREE Full Text
20. ↵
    1. Cannon CP,
    2. Blazing MA,
    3. Giugliano RP,
    4. McCagg A,
    5. White JA,
    6. Theroux P,
    7. et al.

    (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372:2387–297.

    OpenUrlCrossRefPubMed
21. ↵
    1. Masuda J,
    2. Tanigawa T,
    3. Yamada T,
    4. Nishimura Y,
    5. Sasou T,
    6. Nakata T,
    7. et al.

    (2015) Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J 56:278–285.

    OpenUrl
22. ↵
    1. Wang X,
    2. Zhao X,
    3. Li L,
    4. Yao H,
    5. Jiang Y,
    6. Zhang J

    (2016) Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Heart Lung Circ 25:459–465.

    OpenUrlCrossRefPubMed